NewAmsterdam Pharma Company N.V.
NAMS · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | $3,384,368 | $2,037,555 | $2,377,078 | $2,493,630 |
| - Cash | $538,407 | $563,864 | $748,420 | $771,743 |
| + Debt | $266 | $328 | $389 | $448 |
| Enterprise Value | $2,846,227 | $1,474,019 | $1,629,047 | $1,722,335 |
| Revenue | $348 | $19,145 | $2,978 | $12,772 |
| % Growth | -98.2% | 542.9% | -76.7% | – |
| Gross Profit | $348 | $19,145 | $2,978 | $12,772 |
| % Margin | 100% | 100% | 100% | 100% |
| EBITDA | -$71,941 | -$35,590 | -$68,873 | -$111,693 |
| % Margin | -20,672.7% | -185.9% | -2,312.7% | -874.5% |
| Net Income | -$72,005 | -$17,364 | -$39,527 | -$92,177 |
| % Margin | -20,691.1% | -90.7% | -1,327.3% | -721.7% |
| EPS Diluted | -0.61 | -0.15 | -0.34 | -0.98 |
| % Growth | -306.7% | 55.9% | 65.3% | – |
| Operating Cash Flow | -$32,769 | -$37,671 | -$36,468 | -$37,481 |
| Capital Expenditures | -$42 | -$88 | -$16 | -$3 |
| Free Cash Flow | -$32,811 | -$37,759 | -$36,484 | -$37,484 |